The Venture Codex Logo

The Venture Codex

Unisense FertiliTech

Tueager 1, Aarhus N, Midtjylland, 8200, Denmark

Overview

Unisense FertiliTech A/S is a Danish medtech company that develops and manufactures products to improve treatment in the field of assisted reproduction. Its current product portfolio includes the EmbryoScope® time-lapse system, the EmbryoViewer® software and related accessories, which are EU approved and FDA cleared for clinical use in IVF laboratories. The company operates in more than 30 countries and has a pipeline of products under development with commercial potential in the IVF industry. FertiliTech is involved in international collaborations to develop embryo assessment algorithms to improve embryo selection and workflow in the assisted reproduction laboratory. The company intends to use recent proceeds to accelerate global expansion of sales of existing and new products. Founded in 2003 and led by CEO Jens Gundersen, Unisense FertiliTech combines hardware, software and algorithm development in assisted reproduction. Unisense FertiliTech A/S, founded in 2003 and based in Aarhus, Denmark, develops and manufactures products to improve treatment in the field of assisted reproduction. Its core products include the EmbryoScope® Time-lapse system and the EmbryoViewer® Workstation software, both EU approved and FDA cleared for clinical use in IVF laboratories. The company currently operates in more than 30 countries worldwide. In addition to its current hardware and software offerings, Unisense is developing additional products with significant commercial potential within the IVF industry. Unisense received a $24M investment and intends to use the capital to execute its long-term development strategy and to accelerate global expansion of sales for existing and new products. The company is led by CEO Jens Gundersen.

Total raised
$44M
Funding rounds
2
Latest round
Equity
Latest activity
Mar 2013

Industries

  • Biotechnology
  • Manufacturing
  • Medical Device
Visit website

Recent funding

  1. Equity

    Mar 2013

    $20M

  2. Equity

    Dec 2012

    $24M

Team

No current team members are available.